Biocartis Group NV: Biocartis establishes US subsidiary and appoints US General Manager
(Thomson Reuters ONE) -
PRESS RELEASE: 4 April 2017, 07:00 CET
Biocartis establishes US subsidiary and appoints US General Manager
Mechelen, Belgium, 4 April 2017 - Biocartis Group NV (the 'Company' or
'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels:
BCART), today announces the establishment of its US subsidiary, Biocartis US
Inc., and the appointment of Vishal Sikri as its US General Manager. Both are
important next steps in the execution of Biocartis' US strategy following the
announced commercialization agreement with Thermo Fisher Scientific[1] Inc. in
November 2016.
Biocartis is pleased to announce the appointment of Vishal Sikri as the General
Manager for its US operations. Vishal is a highly experienced executive with a
proven global commercial and operational track-record in molecular diagnostics.
Before joining Biocartis, he was Managing Director and VP Commercial Operations
responsible for all global commercial operations of Sysmex Inostics, the
molecular diagnostics' division of Sysmex Corporation (TYO: 6869). Prior to
that, he held various roles within Sysmex America Inc. and Sysmex Corporation,
including amongst others the position of Director New Business Development.
Before joining Sysmex in January 2007, Vishal held different Senior Product
Management roles within Abbott Laboratories. Vishal holds a degree in
Pharmaceutical Sciences (University of Wisconsin) and a Master's in Business
Administration (Loyola University of Chicago).
Vishal Sikri, General Manager of Biocartis US Inc., commented: "I am very
pleased to be leading the team that will build the commercial activities of
Biocartis in the US, an important new market for the Company. I truly believe
that with Idylla(TM), we will make a difference in the US market where there is
a pressing need for easy, rapid and highly accurate oncology diagnostic
solutions."
Hilde Windels, Chief Executive Officer of Biocartis, added: "Vishal has been
championing commercial growth strategies in molecular diagnostics in oncology
for most of his career. With a broad background varying from clinical trial
management to sales & marketing, medical affairs, business development and M&A,
and a particular expertise in liquid biopsy testing and companion diagnostics,
we are confident that Vishal will successfully establish Biocartis in one of the
largest molecular diagnostics markets in the world."
Biocartis expects to start commercial roll-out in the US of its rapid and fully
automated Idylla(TM) platform and its accompanying assays, with a first focus on
oncology research products, in H2 2017. The Company will open its US office in
the New Jersey area.
--- END ---
More information:
Renate Degrave
Manager Corporate Communications & Investor Relations
e-mail rdegrave(at)biocartis.com
tel +32 15 631 729
mobile +32 471 53 60 64
About Biocartis
Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics
(MDx) company providing next generation diagnostic solutions aimed at improving
clinical practice for the benefit of patients, clinicians, payers and industry.
Biocartis' proprietary MDx Idylla(TM) platform is a fully automated sample-to-
result, real-time PCR (Polymerase Chain Reaction) system that offers accurate,
highly reliable molecular information from virtually any biological sample in
virtually any setting. Biocartis launched the Idylla(TM) platform in September
2014. Biocartis is developing and marketing a rapidly expanding test menu
addressing key unmet clinical needs in oncology and infectious diseases. These
areas represent respectively the fastest growing and largest segments of the MDx
market worldwide. Today, Biocartis offers eight oncology tests and two
infectious disease tests. More information: www.biocartis.com. Press Photo
Library available here. Follow us on Twitter: (at)Biocartis_.
Certain statements, beliefs and opinions in this press release are forward-
looking, which reflect the Company or, as appropriate, the Company directors'
current expectations and projections concerning future events such as the
Company's results of operations, financial condition, liquidity, performance,
prospects, growth, strategies and the industry in which the Company operates. By
their nature, forward-looking statements involve a number of risks,
uncertainties, assumptions and other factors that could cause actual results or
events to differ materially from those expressed or implied by the forward-
looking statements. These risks, uncertainties, assumptions and factors could
adversely affect the outcome and financial effects of the plans and events
described herein. A multitude of factors including, but not limited to, changes
in demand, competition and technology, can cause actual events, performance or
results to differ significantly from any anticipated development. Forward-
looking statements contained in this press release regarding past trends or
activities are not guarantees of future performance and should not be taken as a
representation that such trends or activities will continue in the future. In
addition, even if actual results or developments are consistent with the
forward-looking statements contained in this press release, those results or
developments may not be indicative of results or developments in future periods.
As a result, the Company expressly disclaims any obligation or undertaking to
release any update or revisions to any forward-looking statements in this press
release as a result of any change in expectations or any change in events,
conditions, assumptions or circumstances on which these forward-looking
statements are based. Neither the Company nor its advisers or representatives
nor any of its subsidiary undertakings or any such person's officers or
employees guarantees that the assumptions underlying such forward-looking
statements are free from errors nor does either accept any responsibility for
the future accuracy of the forward-looking statements contained in this press
release or the actual occurrence of the forecasted developments. You should not
place undue reliance on forward-looking statements, which speak only as of the
date of this press release.
--------------------------------------------------------------------------------
[1] The agreement was signed with Fisher HealthCare, part of Thermo Fisher
Scientific Inc.
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Biocartis Group NV via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="betterU Education Corp. Expands Global Footprint to Australia and New ZealandDatum: 04.04.2017 - 07:01 Uhr
Sprache: Deutsch
News-ID 534164
Anzahl Zeichen: 7875
contact information:
Town:
Mechelen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 181 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Biocartis Group NV: Biocartis establishes US subsidiary and appoints US General Manager"
steht unter der journalistisch-redaktionellen Verantwortung von
Biocartis Group NV (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
